20240024302. SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY simplified abstract (BETH ISRAEL DEACONESS MEDICAL CENTER, INC.)
SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY
Organization Name
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Inventor(s)
Jeffrey E. Saffitz of Waban MA (US)
Bruce D. Hammock of Davis CA (US)
Sung Hee Hwang of Woodland CA (US)
SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240024302 titled 'SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY
Simplified Explanation
The patent application describes methods for preventing, mitigating, decreasing, reversing, and/or treating arrhythmogenic cardiomyopathy (ACM) in a subject. This is achieved by administering an effective amount of a compound of formula I, a compound of formula II, or a compound of formula III to the subject.
- The compound of formula I, compound of formula II, or compound of formula III is administered to a subject in need of treatment for ACM.
- The compounds are effective in preventing, mitigating, decreasing, reversing, and/or treating ACM.
- The compounds are administered in an amount that is effective for the desired treatment outcome.
- The specific values of R, R, R, N, R, R, R, M, R, R, and P are defined in the patent application.
Potential Applications:
- Treatment of arrhythmogenic cardiomyopathy (ACM)
- Prevention of ACM in individuals at risk
- Mitigation of ACM symptoms
- Reversal of ACM progression
Problems Solved:
- Lack of effective treatment options for arrhythmogenic cardiomyopathy
- Limited methods for preventing or mitigating ACM
- Inadequate means for reversing ACM progression
Benefits:
- Improved treatment outcomes for individuals with ACM
- Potential to prevent or delay the onset of ACM
- Reduction in ACM-related symptoms and complications
- Possibility of reversing the progression of ACM
Original Abstract Submitted
provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating arrhythmogenic cardiomyopathy (acm) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula i, a compounds of formula ii, or a compound of formula iii (i) (ii), (iii) wherein r, r, r, n, r, r, r, m, r, r, and p are as defined herein.
